Grifols, S.A. (BME:GRF)
Spain · Delayed Price · Currency is EUR 9.88
+0.22 (2.30%)
Oct 6, 2026, 5:35 PM CET
Grifols Revenue
Grifols had revenue of 1.87B EUR in the quarter ending June 30, 2026, a decrease of -0.91%. This brings the company's revenue in the last twelve months to 7.42B, down -0.33% year-over-year. In the year 2025, Grifols had annual revenue of 7.52B with 4.33% growth.
Revenue (ttm)
7.42B
Revenue Growth
-0.33%
P/S Ratio
0.78
Revenue / Employee
293.81K
Employees
25,000
Market Cap
5.79B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.52B | 312.00M | 4.33% |
| Dec 31, 2024 | 7.21B | 620.02M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
| Dec 31, 2022 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | 5.10B | 611.97M | 13.64% |
| Dec 31, 2018 | 4.49B | 168.65M | 3.91% |
| Dec 31, 2017 | 4.32B | 268.24M | 6.62% |
| Dec 31, 2016 | 4.05B | 115.27M | 2.93% |
| Dec 31, 2015 | 3.93B | 579.18M | 17.26% |
| Dec 31, 2014 | 3.36B | 613.65M | 22.38% |
| Dec 31, 2013 | 2.74B | 120.79M | 4.61% |
| Dec 31, 2012 | 2.62B | 825.33M | 45.96% |
| Dec 31, 2011 | 1.80B | 804.88M | 81.24% |
| Dec 31, 2010 | 990.73M | 77.54M | 8.49% |
| Dec 31, 2009 | 913.19M | 98.88M | 12.14% |
| Dec 31, 2008 | 814.31M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Almirall | 1.16B |
| Laboratorios Farmaceuticos Rovi | 773.05M |
| Faes Farma | 711.06M |
| Laboratorio Reig Jofre | 337.73M |
| Clínica Baviera | 320.67M |
| Prim, S.A. | 250.65M |
| Pharma Mar | 218.64M |
| Atrys Health | 147.68M |
Grifols News
- 12 days ago - Grifols says Canada plasma license suspension has no impact - Reuters
- 13 days ago - After Hours Most Active for Sep 23, 2026 : WBD, GRAB, NVDA, NIO, CMCSA, TTD, BMY, GRFS, PBR, RKT, RBLX, O - Nasdaq
- 13 days ago - Health Canada suspends Grifols’s licence at Winnipeg plasma location - CBC News
- 1 month ago - Grifols completes clinical portion of SPARTA trial - TheFly
- 1 month ago - Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 2 months ago - Grifols says EXCELL Phase 3 trial timeline not ‘new development or a delay’ - TheFly
- 2 months ago - Grifols Q2 Earnings Call Highlights - MarketBeat
- 2 months ago - Grifols Earnings Call Transcript: Q2 2026 - Transcripts